Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior

The purpose of study is to determine if modafinil promotes cocaine abstinence and reduces
HRB in cocaine dependent subjects. Modafinil (300 mg/day) or placebo will be administered
in an 8-week double-blind trial to patients meeting diagnostic criteria for cocaine
dependence in conjunction with Cognitive Behavioral Therapy (CBT).

Inclusion Criteria:

1. 18 - 60 years;

2. Current DSM-IV diagnosis of cocaine dependence;

3. Using cocaine at least 8 days in a consecutive 30 day period over the 60 day period
immediately preceding study entry (If subject was receiving inpatient substance abuse
treatment within 30 days prior to screening, subject must have been using cocaine at
least 8 days in a consecutive 30 day period over the 60 day period immediately
preceding admission to inpatient treatment); 4.)Having a negative urine toxicology
(BE) test during screening (no less than 5 days prior to randomization) and a
negative urine toxicology (BE) test on the day of randomization. Repeat testing
allowed until required negative BE results are obtained;

4. Able to provide written informed consent and to comply with all study procedures;

5. Women must be surgically sterile, at least two years postmenopausal, or, if of
childbearing potential, be using a medically accepted method of birth control and
agree to continue use of this method for at least 30 days after the last dose of
study drug (i.e. barrier method with spermicide, steroidal contraceptive [oral and
implanted, including Depo-Provera, contraceptives must be used in conjunction with a
barrier method], or intrauterine device [IUD]).

Exclusion Criteria:

1. Currently dependent on any substance other than cocaine or nicotine;

2. Current Neurological or psychiatric disorders, such as psychosis, bipolar illness,
organic brain disease, dementia, or any diseases that require psychotropic
medications;

3. Serious medical illnesses, including but not limited to; uncontrolled hypertension,
significant heart disease (including a history of myocardial infarction, angina,
mitral valve prolapse, left ventricular hypertrophy, palpitations, and arrhythmia),
hepatic disease, renal disease, or any serious, potentially life-threatening or
progressive medical illness that may compromise patient safety or study conduct;

4. Received a drug with known potential for toxicity to a major organ system within the
month prior to entering treatment including, but not limited to: chemotherapeutic
agents for neoplastic disease (i.e. methotrexate, vincristine, vinblastine,
fluorouracil), agents used for parasitic infections, isoniazid, chlorambucil,
dactinomycin, chloramphenicol, immunosuppressive and cytotoxic agents (i.e.
cyclosporine, tacrolimus), indomethacin, protease inhibitors, amphotericin B,
cephalosporins, aminoglycosides, interferon, and sulfonamides;

5. Clinically significant abnormal laboratory values (see Appendix A);

6. Has any disease of the gastrointestinal system, liver, or kidneys which could result
in altered metabolism or excretion of the study medication (history of major
gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or
history of chronic gastrointestinal disorders (ulcerative colitis, regional
enteritis, or gastrointestinal bleeding);

7. Known hypersensitivity or allergy to modafinil, or receiving chronic therapy with any
medication that could interact adversely with modafinil, including propranolol,
phenytoin, warfarin and diazepam;

8. Took monoamine oxidase inhibitors (MAOI) within 30 days prior to randomization;

9. Taking or has taken an investigational drug within 60 days prior to randomization;

10. If female and of child-bearing capacity, tests positive on a urine pregnancy test, is
lactating, has had three or more days of amenorrhea beyond expected menses at the
time of the first dose of study medication, is contemplating pregnancy in the next 6
months, or is not using an effective contraceptive method;

11. Received therapy with any opiate-substitute (methadone, LAAM, buprenorphine) within
60 days of study enrollment.